✦ LIBER ✦

Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: A multicenter randomized controlled trial

✍ Scribed by Akinori Kasahara; Norio Hayashi; Naoki Hiramatsu; Masahide Oshita; Hideki Hagiwara; Kazuhiro Katayama; Michio Kato; Manabu Masuzawa; Harumasa Yoshihara; Yutaka Kishida; Yoji Shimizu; Atsuo Inoue; Hideyuki Fusamoto; Takenobu Kamada

Publisher: John Wiley and Sons
Year: 1995
Tongue: English
Weight: 882 KB
Volume: 21
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.1840210205

No coin nor oath required. For personal study only.

✦ Synopsis

The aim of this study was to determine whether 12 months course of interferon alfa (IFN-a) therapy could improve the beneficial effect of IFN in chronic hepatitis C. Eighty-eight patients were treated with natural IFNa for either 28 weeks (45 cases) or 52 weeks (43 cases). Sustained response was achieved in 15 (33.3%) of 45 cases treated for 28 weeks and in 23 (53.5%) of 43 cases treated for 52 weeks. Transient response with relapse of alanine transaminase (ALT) after completion of therapy was observed in 13 cases (28.9%) treated for 28 weeks and in 4 cases (9.3%) treated for 52 weeks. Thus, ALT relapse was suppressed by prolonged IFN treatment. No response was found in 17 cases (37.8%) treated for 28 weeks and in 16 cases (37.2%) treated for 52 weeks, indicating that approximately 38% of the patients with chronic hepatitis C were resistant to IFN therapy even with prolonged treatment. The rate of sustained response was significantly higher in patients with type 2a or 2b than in those with type lb. Even in type l b cases, it was higher in the 52-week treatment group than in the 28-week treatment group, and the rate of transient response was lower in the 52-week treatment group, indicating that relapse in type l b cases was suppressed by prolonged IFN therapy. IFN therapy was not effective for patients with advanced liver fibrosis. In multivariate regression analysis viral genotype and pretreatment level of serum hepatitis C virus (HCV) RNA were correlated independently with sustained response.

📜 SIMILAR VOLUMES

Treatment of chronic hepatitis C with co

Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial

✍ M J Tong; K R Reddy; W M Lee; P J Pockros; J C Hoefs; E B Keeffe; F B Hollinger; 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 222 KB 👁 2 views

AND THE CONSENSUS INTERFERON STUDY GROUP 15 tion. Efficacy was assessed by normalization of serum alanine This multicenter, randomized, controlled, double-blind, transaminase (ALT) concentration and decrease in serum hepphase III study in 704 patients with chronic hepatitis C infecatitis C virus (HC

Better efficacy of a 12-month interferon

Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: A multicenter, controlled, randomized trial

✍ Jean-Louis Payen; Jacques Izopet; Virginie Galindo-Migeot; Valérie Lauwers-Cance 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 320 KB 👁 2 views

We studied the efficacy of three interferon alfa-2b (IFN-2b) regimens for the retreatment of patients with chronic hepatitis C (CHC) with prior complete response followed by relapse. Consecutive patients with CHC who had a complete biochemical response but relapse after a first course of 6 months of

Response to higher doses of interferon a

Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: A randomized multicenter trial

✍ K L Lindsay; G L Davis; E R Schiff; H C Bodenheimer; L A Balart; J L Dienstag; R 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

JANICE ALBRECHT, 12 AND THE HEPATITIS INTERVENTIONAL THERAPY GROUP\* with continued therapy at that dose; however, a propor-To evaluate response rates to 3, 5, or 10 million units tion of patients who do not respond to 12 weeks of treat-(MU) of interferon alfa-2b, given thrice weekly, and to ment wi

A multicenter randomized controlled tria

A multicenter randomized controlled trial of recombinant interferon-α2b in patients with acute transfusion-associated hepatitis C

✍ Pietro Lampertico; Mariagrazia Rumi; Raffaella Romeo; Antonio Craxi; Roberta Sof 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 462 KB 👁 1 views

Combination therapy with thymosin α1 and

Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial

✍ Kenneth E. Sherman; Maria Sjogren; Robin L. Creager; Melissa A. Damiano; Stephen 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 1 views

Hepatitis C is a major cause of liver disease leading to cirrhosis. Although interferon (IFN) is the only approved therapy, treatment is characterized by low response rates and dose-limiting side effects. We evaluated the addition of thymosin ␣1 (TA1), an immunomodulatory peptide, to the standard tr

Interferon and ursodeoxycholic acid comb

Interferon and ursodeoxycholic acid combined therapy in the treatmet of chronic viral C hepatitis: Results from a controlled randomized trial in 80 patients

✍ Eveline Boucher; Hervé Jouanolle; Patrice Andre; Annick Ruffault; Dominique Guya 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 744 KB

Because 70% to 75% of patients with chronic hepatitis C either do not respond to or relapse after interferon (IFN) therapy, and because ursodeoxycholic acid (UDCA) has been shown to reduce aminotransferase lev-TOLOGY 199% 21 :322-327.